The dose-response curve between 8 and 12 mg shows diminishing returns, meaning 10 mg captures most of the benefit while potentially reducing some of the dose-related side effects seen at 12 mg
PSPeptides supplies this peptide with full third-party tested CoA documentation at 99%+ purity
Hudgens JL, Sugg KB, Grekin JA, Gumucio JP, Bedi A, Mendias CL
A useful way to think about them is this: they do not do the work for you
Practitioners are already using this approach with success in: Autoimmune conditions (like arthritis, Hashimotos, and celiac-related issues) Post-COVID complications (including Long COVID and MIS-C) Metabolic dysfunction (insulin resistance, chronic inflammation) Neurological issues (brain fog, mood changes from gut-brain disruption) What Research Shows Clinical studies on Larazotide demonstrate: A measurable reduction in gut permeability markers Improved gut symptom scores Lower inflammatory cytokine levels A strong safety record with minimal side effects Patients typically notice improvement in 714 days , with full benefits within 46 weeks
01163-7/asset/574129d4-809d-4296-9b7e-10d493ffcfad/main.assets/gr1_lrg.jpg)
